Iovance Biotherapeutics, INC 8-K filings

Iovance Biotherapeutics reports the retirement of a board member, nomination of a new director, and amendments to its bylaws.

The FDA has lifted a partial clinical hold on Iovance's IOV-LUN-202 trial, allowing patient enrollment to resume for their LN-145 TIL cell therapy in non-small cell lung cancer.

Iovance Biotherapeutics updated its corporate presentation, emphasizing the launch of AMTAGVI, its approved melanoma treatment, and progress in its broader TIL therapy pipeline.

Iovance Biotherapeutics announced its fourth quarter and full year 2023 financial results, highlighted by the ongoing launch of Amtagvi, the first FDA-approved T-cell therapy for a solid tumor.

Iovance Biotherapeutics successfully closed a share offering, raising approximately $197.1 million in net proceeds.

Iovance Biotherapeutics has announced the pricing of a $211 million underwritten offering of common stock to support the commercial launch of AMTAGVI and fund ongoing clinical programs.

Iovance Biotherapeutics' AMTAGVI (lifileucel) has received accelerated FDA approval as the first T-cell therapy for a solid tumor, specifically for advanced melanoma after prior treatments.

Iovance Biotherapeutics updated its corporate presentation, showcasing advancements in its tumor-infiltrating lymphocyte (TIL) therapy platform and pipeline.